Biodexa Pharmaceuticals (NASDAQ:BDRX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Biodexa Pharmaceuticals (NASDAQ:BDRX) from a hold rating to a sell rating in a report published on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Down 0.9%

Shares of BDRX opened at $1.08 on Friday. The firm’s 50 day moving average is $2.79 and its 200-day moving average is $5.06. Biodexa Pharmaceuticals has a 12-month low of $1.04 and a 12-month high of $47.79.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.